GHRP-2 dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 100 mcg dose equals 4 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical GHRP-2 dose is 0.1 mg (100 to 300 mcg per injection, 2 to 3 times daily. Doses above ~1 mcg/kg show diminishing returns.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 2-3x daily. Half-life of 0.5 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: acute hunger; head pressure or flushing; water retention; vivid dreams. Stop or reduce dose if tolerability breaks down.

Why this dose

Hexapeptide agonist of the growth-hormone secretagogue receptor (GHS-R1a). Suppresses hypothalamic somatostatin tone and stimulates pituitary somatotrophs, producing a pulsatile GH release with secondary cortisol, prolactin, and ACTH elevation.

The typical dose (0.1 mg) reflects 100 to 300 mcg per injection, 2 to 3 times daily. Doses above ~1 mcg/kg show diminishing returns.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

GHRP-2 is administered via the subcutaneous, intranasal, intravenous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Intranasal delivery uses a metered spray; tilt the head slightly forward and breathe gently while spraying.

Onset of action runs around 15 minutes after administration. Peak effect lands near 30 minutes post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Short ~15 to 60 minute plasma half-life produces a brief GH pulse that returns to baseline within 2 to 3 hours. Multi-daily dosing aligns with endogenous pulse windows.

Cycling and tolerance

Anecdotal protocols run 8 to 12 weeks on, then 4 weeks off. No controlled human cycling data.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Hexapeptide ghrelin-receptor agonist that stimulates pulsatile GH release within 15 to 30 minutes
• Strongest appetite signal among GHRPs at standard doses; centrally mediated via NPY/AgRP
• Produces measurable cortisol and prolactin rise (more than ipamorelin, less than GHRP-6)
• Approved in Japan as pralmorelin for GH-deficiency diagnostic provocation; not FDA approved
• Anecdotal protocols use 100 to 300 mcg subcutaneously 2 to 3 times daily on an empty stomach
• Banned by WADA under S2; detection methods validated in accredited labs

Side effects and interactions

Common side effects

• acute hunger
• head pressure or flushing
• water retention
• vivid dreams
• tingling at injection site

Notable interactions

• insulin (moderate): sustained GH can blunt insulin sensitivity over weeks
• corticosteroids (moderate): blunt GH response and amplify cortisol load
• CJC-1295 (minor): synergistic GH release; commonly co-administered for larger pulse
• sermorelin (minor): additive GH release via parallel GHRH and ghrelin pathways

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full GHRP-2 profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not scheduled in US (research chemical); approved diagnostic in Japan

Pregnancy

Insufficient data; not recommended

Legal status

Not FDA approved; approved in Japan as pralmorelin (diagnostic); research-use-only grey market in US/EU; banned by WADA

Do not use if

• pregnancy
• active malignancy
• history of pituitary tumor
• uncontrolled diabetes
• severe insulin resistance

Related research